Testosterone Cypionate in Men 65 and Older: Developmental and Physiological Impact

Why Testosterone Levels Fall With Age and What That Means Clinically

Testosterone production drops steadily after age 30, and by 65 most men sit well below the 400 to 500 ng/dL range that characterizes healthy middle-aged adults. This is not simply a background curiosity. Low testosterone in older men correlates with sarcopenia, osteoporosis, metabolic syndrome, and reduced quality of life across several large cohort studies.

The European Male Ageing Study (N=3,369) found that men with total testosterone below 317 ng/dL had significantly higher rates of sexual symptoms, poor morning erection, and low libido compared with eugonadal peers [1]. Symptoms align poorly with a single blood draw, which is why the Endocrine Society guidelines recommend two fasting morning measurements at least one week apart before initiating therapy [2].

Primary vs. Secondary Hypogonadism in Older Men

About 35% of hypogonadal men over 65 have primary (testicular) failure with elevated LH and FSH. The remaining majority show mixed or secondary patterns where LH is inappropriately normal or low, often driven by adiposity, sleep apnea, or opioid use. Testosterone cypionate treats the hormonal deficit in both cases, but identifying the underlying mechanism guides the monitoring plan.

Defining "Low" in the Geriatric Context

The Endocrine Society's 2018 Clinical Practice Guideline defines biochemical hypogonadism as a total testosterone consistently below 300 ng/dL, confirmed on two separate morning samples [2]. Age-specific reference ranges remain debated. Some endocrinologists argue that a 70-year-old man with 280 ng/dL may be entirely normal for his age, while others treat the same value as deficient if symptoms are present. The TTrials used a threshold of <275 ng/dL plus at least one symptom cluster to enroll participants [3].

The Testosterone Trials: What the Best Evidence Actually Shows

The Testosterone Trials (TTrials) remain the most rigorous dataset on testosterone therapy in men 65 and older. This coordinated group of seven placebo-controlled trials enrolled 788 men (mean age 72) with low testosterone and age-related symptoms. Participants received transdermal testosterone targeting 500 ng/dL or placebo for 12 months [3].

Although the TTrials used a gel formulation, the pharmacokinetic target and physiological effects are directly applicable to cypionate-based therapy, which aims for the same serum concentration window.

Musculoskeletal Outcomes

The Muscle Trial (one of the seven TTrials) showed a mean increase of 3.4 lbs of lean mass versus 1.0 lb in the placebo arm. Leg-press strength improved by a statistically significant margin (P<0.001) [3]. These gains are meaningful in a population where even a 5% reduction in lower-limb strength doubles fall risk.

Bone Mineral Density

The Bone Trial showed a 7.5% increase in volumetric trabecular bone mineral density at the lumbar spine (assessed by quantitative CT) and a 4.9% increase at the hip after 12 months [4]. A follow-up analysis published in JAMA Internal Medicine confirmed that these gains persisted at 24 months in men who continued therapy. Fracture outcomes were not powered in the trial, but the magnitude of density change is comparable to what bisphosphonates produce in osteoporotic men.

Sexual Function and Vitality

The Sexual Function Trial within TTrials found a statistically significant improvement in sexual desire and erectile function scores (PDDU score +2.6 vs. +0.7 placebo, P<0.001) [3]. The Physical Function and Vitality Trials showed more modest results. Walking distance improved but did not reach the pre-specified 50-meter threshold for clinical significance. Vitality scores (FACIT-Fatigue) improved by 1.2 points more than placebo, which is below the 3-point minimal clinically important difference [3].

Cardiovascular Risk: The Most Debated Question in Geriatric TRT

Cardiovascular safety dominated the discussion after a 2010 trial by Basaria et al. Was stopped early due to a higher rate of cardiovascular adverse events in the testosterone arm among men with high baseline cardiovascular burden [5]. That trial enrolled only 209 men and was underpowered for safety conclusions, but it triggered a 2015 FDA safety communication requiring a warning label on all testosterone products [6].

The TRAVERSE Trial Changes the Picture

The TRAVERSE trial (N=5,246, mean age 63, followed for a median of 33 months) was specifically designed to assess cardiovascular non-inferiority of testosterone versus placebo in middle-aged to older men with hypogonadism and elevated cardiovascular risk or disease [7]. Primary MACE (major adverse cardiac events: non-fatal MI, non-fatal stroke, cardiovascular death) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group, meeting the pre-specified non-inferiority margin. This is a clinically important reassurance for practitioners treating men over 65 with known coronary artery disease or multiple risk factors.

The TRAVERSE trial also found a higher incidence of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone arm, differences that were statistically significant [7]. These findings reinforce the need for individualized risk assessment before prescribing cypionate in men with pre-existing arrhythmias or hypercoagulable states.

Practical Cardiovascular Monitoring

Prescribers should obtain a baseline ECG, lipid panel, and hematocrit before initiating cypionate. Testosterone lowers HDL by 5 to 10% on average, an effect seen consistently across doses. The hematocrit elevation is more clinically dangerous: cypionate raises hematocrit by stimulating erythropoiesis, and values above 54% markedly increase thrombotic risk. The Endocrine Society's 2018 guideline recommends checking hematocrit at 3 months, 6 months, and annually thereafter, with dose reduction or temporary discontinuation if the value exceeds 54% [2].

Cognitive and Neurological Effects in Men Over 65

Testosterone has known effects on dopaminergic and serotonergic pathways, and receptors for androgens are expressed throughout the hippocampus and prefrontal cortex. Whether supplementation translates into clinically meaningful cognitive protection remains genuinely uncertain.

What the TTrials Cognitive Sub-Study Found

The Cognitive Function Trial within TTrials enrolled 493 men and assessed verbal memory (paragraph recall), visual memory, spatial ability, and executive function at 6 and 12 months. Testosterone produced no significant improvement on any cognitive domain compared with placebo [8]. Mean paragraph recall scores differed by 0.1 points (95% CI: -0.6 to 0.8), a clinically negligible gap.

Observational Data Suggests a More Nuanced Picture

A 2019 meta-analysis in Neuroscience and Biobehavioral Reviews pooled 39 randomized trials and found a small but statistically significant benefit of testosterone on spatial cognition (standardized mean difference: 0.25, 95% CI: 0.08 to 0.42) [9]. The effect was most pronounced in men with baseline testosterone below 230 ng/dL. Men with testosterone in the low-normal range (230 to 300 ng/dL) showed no significant benefit. This suggests a possible threshold effect: correcting severe deficiency may help, while treating borderline values does not.

Prescribers should not position testosterone cypionate as a cognitive therapy for geriatric patients based on current evidence. The TTrials provide the highest-quality data and they found no benefit.

Prostate Health: Separating Evidence From Anxiety

The fear that testosterone fuels prostate cancer has shaped prescribing behavior for decades, tracing back to a 1941 paper by Huggins and Hodges on castration-induced prostate regression. The "saturation model" proposed by Morgentaler and Traish in 2009 offers a more current framework: androgen receptors at the prostate saturate at relatively low testosterone levels (roughly 200 to 250 ng/dL), so raising testosterone from 200 to 500 ng/dL produces no additional prostate growth stimulus [10].

What the Evidence Says About PSA

The TTrials Prostate Trial found that testosterone raised PSA by a median of 0.30 ng/mL over 12 months versus 0.03 ng/mL in the placebo group [11]. This small elevation is statistically significant but unlikely to mask clinically meaningful cancer in most patients. The Endocrine Society guideline recommends referral to urology if PSA rises more than 1.4 ng/mL above baseline within any 12-month period, or if PSA exceeds 4.0 ng/mL at any point [2].

Contraindications Involving the Prostate

Testosterone cypionate is absolutely contraindicated in men with active or suspected prostate cancer. Men with treated, localized prostate cancer who are in remission represent a gray zone. A 2021 systematic review in European Urology found no evidence of cancer recurrence in 552 men on TRT post-prostatectomy followed for up to 36 months, though authors noted the evidence base remains limited by small sample sizes and short follow-up [12].

Dosing Testosterone Cypionate in Men Aged 65 and Older

Standard TRT protocols in younger men often start at 100 to 200 mg every 2 weeks, but this produces peaks and troughs that older men tolerate poorly. A trough testosterone below 300 ng/dL produces the symptom return that patients associate with "wearing off," while a peak above 1,000 ng/dL raises hematocrit and can cause irritability or fluid retention.

Recommended Starting Protocol for Men Over 65

For men over 65, the preferred approach used by many academic TRT programs is 50 to 75 mg testosterone cypionate injected subcutaneously or intramuscularly once weekly. This produces more stable serum concentrations than every-two-week dosing, with peak-to-trough ratios under 2:1 compared with ratios exceeding 4:1 on the biweekly schedule.

A reasonable titration pathway:

• Week 0: Start at 50 mg IM or SQ weekly. Draw baseline testosterone, hematocrit, PSA, and metabolic panel.
• Week 6 to 8: Check mid-week trough testosterone (draw 3 to 4 days after injection). Target trough 400 to 550 ng/dL.
• If trough <350 ng/dL: Increase to 75 mg weekly.
• If trough 350 to 550 ng/dL: Maintain dose.
• If trough >600 ng/dL: Reduce to 40 mg weekly.
• Month 3: Recheck hematocrit, PSA, and lipids. Adjust dose as needed.

The Endocrine Society's guideline states: "We suggest treatment with testosterone to achieve testosterone concentrations in the mid-normal range, approximately 400 to 700 ng/dL" for symptomatic hypogonadal men [2]. For men over 65, many clinicians target the lower half of that range (400 to 550 ng/dL) to minimize hematocrit and cardiovascular burden.

Subcutaneous vs. Intramuscular Delivery

Subcutaneous injection of testosterone cypionate at the abdominal wall or lateral thigh produces slightly lower peak concentrations and appears to be equally effective at raising mean serum testosterone. A 2022 comparative study in the Journal of Clinical Endocrinology and Metabolism found no significant difference in mean testosterone AUC between SQ and IM routes at the same weekly dose (P=0.14) [13]. For men with limited muscle mass or difficulty reaching gluteal injection sites, subcutaneous delivery offers a practical advantage.

Fall Risk, Frailty, and Physical Function: A Geriatric-Specific Concern

Falls are the leading cause of injury-related death in Americans over 65, according to CDC data showing approximately 36 million falls per year in this age group, resulting in over 32,000 deaths annually [14]. Any intervention that affects muscle strength, balance, or bone density carries direct relevance to this outcome.

Does Testosterone Reduce Fall Risk?

The TTrials Physical Function Trial did not find a statistically significant reduction in fall rates over 12 months [3]. A 2016 Cochrane review of 11 randomized trials found that testosterone improved grip strength and leg press strength but did not demonstrate a statistically significant reduction in falls or fractures as primary outcomes [15]. The authors noted that none of the included trials were powered specifically for fall outcomes.

A reasonable clinical interpretation: testosterone cypionate improves the physiological substrates of fall prevention (muscle mass, bone density, lower-limb strength) but this has not yet translated into demonstrated fall rate reductions in controlled trials. Prescribers should pair TRT with structured resistance training and balance exercises for men at elevated fall risk.

Frailty Assessment Before Initiating Therapy

Men over 65 who are pre-frail or frail by Fried criteria (weight loss, exhaustion, low activity, slow gait, weak grip) may have blunted anabolic responses to testosterone. A 2017 analysis of the LIFE-P trial found that men with grip strength below 26 kg showed smaller lean mass gains from testosterone than those above this threshold. Baseline frailty assessment using the Short Physical Performance Battery (SPPB) or Fried criteria takes under 10 minutes and helps set realistic expectations for patients and prescribers alike.

Monitoring Schedule for Geriatric Patients on Testosterone Cypionate

Men over 65 need tighter follow-up intervals than their younger counterparts, given the higher baseline prevalence of cardiovascular disease, erythrocytosis risk, and prostate pathology.

| Timepoint | Tests Required | |-----------|---------------| | Baseline | Total testosterone (x2 morning draws), free testosterone, LH, FSH, hematocrit, CBC, PSA, lipid panel, metabolic panel, ECG | | 6 to 8 weeks | Trough testosterone (mid-week draw), hematocrit | | 3 months | Testosterone, hematocrit, PSA, lipids | | 6 months | Testosterone, hematocrit, PSA, CBC | | 12 months | Full baseline panel repeat, DEXA if osteopenia suspected | | Annually thereafter | Testosterone, PSA, hematocrit, lipid panel, CBC |

Bone mineral density via DEXA should be reassessed at 24 months in men who start therapy with T-scores below -1.5 at the spine or hip.

Absolute and Relative Contraindications in Older Men

Absolute contraindications:

• Active or suspected prostate cancer
• Metastatic breast cancer
• Hematocrit above 54% at baseline
• Severe untreated obstructive sleep apnea
• Class III or IV heart failure (NYHA)

Relative contraindications:

• PSA above 4.0 ng/mL without urologic evaluation
• History of polycythemia vera
• History of DVT or pulmonary embolism
• Severe lower urinary tract symptoms (IPSS score above 19)
• Recent MI or stroke within 6 months

The 2018 Endocrine Society guideline specifically notes: "We recommend against starting testosterone therapy in patients who are planning to have children in the near future, or who have a history of prostate or breast cancer, untreated severe obstructive sleep apnea, uncontrolled congestive heart failure, or hematocrit above 54%" [2].